355 related articles for article (PubMed ID: 19524180)
1. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
2. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
3. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
[TBL] [Abstract][Full Text] [Related]
4. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
5. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
7. [Bromocriptine treatment of invasive giant prolactinomas prior to comprehensive treatments: results of a long-term follow up].
Zhang HW; Yu CJ; Sun W; Yang J; Yan CX; Cun EH
Zhonghua Wai Ke Za Zhi; 2006 Nov; 44(22):1555-7. PubMed ID: 17359664
[TBL] [Abstract][Full Text] [Related]
8. Macroprolactinomas and epilepsy.
Deepak D; Daousi C; Javadpour M; MacFarlane IA
Clin Endocrinol (Oxf); 2007 Apr; 66(4):503-7. PubMed ID: 17371466
[TBL] [Abstract][Full Text] [Related]
9. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
[TBL] [Abstract][Full Text] [Related]
10. Gamma knife radiosurgery for medically and surgically refractory prolactinomas.
Pouratian N; Sheehan J; Jagannathan J; Laws ER; Steiner L; Vance ML
Neurosurgery; 2006 Aug; 59(2):255-66; discussion 255-66. PubMed ID: 16883166
[TBL] [Abstract][Full Text] [Related]
11. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
12. Microprolactinomas in males treated by transsphenoidal surgery.
Wolfsberger S; Czech T; Vierhapper H; Benavente R; Knosp E
Acta Neurochir (Wien); 2003 Nov; 145(11):935-40; discussion 940-1. PubMed ID: 14628197
[TBL] [Abstract][Full Text] [Related]
13. Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome.
Iglesias P; Bernal C; Villabona C; Castro JC; Arrieta F; Díez JJ
Clin Endocrinol (Oxf); 2012 Aug; 77(2):281-7. PubMed ID: 22288612
[TBL] [Abstract][Full Text] [Related]
14. [Treatment strategy of pituitary invasive prolactinomas].
Wu ZB; Yu CJ
Zhonghua Wai Ke Za Zhi; 2009 Jan; 47(2):123-7. PubMed ID: 19563008
[TBL] [Abstract][Full Text] [Related]
15. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up.
Berinder K; Stackenäs I; Akre O; Hirschberg AL; Hulting AL
Clin Endocrinol (Oxf); 2005 Oct; 63(4):450-5. PubMed ID: 16181238
[TBL] [Abstract][Full Text] [Related]
16. Acute complications of dopamine agonist treatment for macroprolactinoma - how uncommon?
Nadesapillai S; Balcere I; Kaye AH; Tress BM; Colman PG
J Clin Neurosci; 2004 Nov; 11(8):825-8. PubMed ID: 15519856
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
18. Treatment of macroprolactinomas at Auckland Hospital 1975-91.
Wallace EA; Holdaway IM
N Z Med J; 1995 Feb; 108(994):50-2. PubMed ID: 7885646
[TBL] [Abstract][Full Text] [Related]
19. A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma.
Acquati S; Pizzocaro A; Tomei G; Giovanelli M; Libè R; Faglia G; Ambrosi B
J Neurosurg Sci; 2001 Jun; 45(2):65-9. PubMed ID: 11533529
[TBL] [Abstract][Full Text] [Related]
20. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.
Kontogeorgos G; Horvath E; Kovacs K; Coire C; Lloyd RV; Scheithauer BW; Smyth HS
Acta Neuropathol; 2006 Jan; 111(1):46-52. PubMed ID: 16328513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
